Bacterial biofilms (BB) are clusters of bacteria embedded in their own matrix, associated with chronic infections with higher tolerance to antibiotics. Secondary messenger cyclic di-GMP (cdGMP) promotes biofilm formation and is a potential target in the BB disruption strategies. The EU-funded DRIPBEAT project aims to repurpose drugs for targeting the cdGMP pathway and biofilms, increasing the antibiotic susceptibility of clinically important Pseudomonas aeruginosa strains. The interdisciplinary study will combine next-generation sequencing technology and protein structural modelling in a murine model of lung epithelial cell infection. The results will provide new insights into the cdGMP pathway and the selection of appropriate compounds for BB treatment.